MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Core Insights - MediciNova, Inc. announced the acceptance of an abstract for the presentation of the COMBAT-ALS Phase 2b/3 study of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) at the 2024 Annual NEALS Meeting [1] - The presentation will be conducted by Dr. Björn Oskarsson, the lead Principal Investigator, on October 23, 2024 [2] - MN-166 (ibudilast) is a small molecule compound targeting neurodegenerative diseases and is in late-stage clinical development for ALS, progressive MS, and DCM, among others [2][3] Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company with a focus on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [3] - The company has a pipeline of 11 clinical programs, with MN-166 (ibudilast) being the lead asset currently in Phase 3 trials for ALS and DCM [3] - MN-001 (tipelukast), another compound in development, has been evaluated in Phase 2 trials for idiopathic pulmonary fibrosis and is ongoing for metabolic-associated fatty liver disease [3]